Ginkgo launches antibody consortium with AbbVie, Takeda, argenx, Lundbeck using federated learning
snikolov · x · 2026-09-29
Ginkgo Bioworks and Apheris have launched the Antibody Developability Consortium with founding members AbbVie, Takeda, argenx, and Lundbeck.
- Members contribute proprietary antibody sequences; Apheris's federated learning lets them co-fund and improve models without sharing raw proprietary data
- Ginkgo Datapoints' antibody developability service runs the assays and fills remaining capacity from public sources, targeting 10,000 antibodies total
- Goal: build the field's largest standardized antibody developability dataset to help pharma predict manufacturability and developability risks earlier
The consortium is open to additional pharma and biotech members.
Related event: Ginkgo and Pharma Partners Launch Antibody Developability Consortium(2 posts)→
More from Venture
- Colossus 2's 1.2M B200s could generate ~$400B/year in tokens at DeepSeek Flash rates — bookwormengr · 2026-11-16
- Anthropic's amended S-1 shows slowing growth; full-year revenue seen at $55-57B — bookwormengr · 2026-11-16
- AI compute stocks keep sliding premarket: Nebius -6.9%, CoreWeave -6%, Oracle -3.2% — GaryMarcus · 2026-11-16
- Freshworks alums raise $53M for AI-native CRM to challenge Salesforce, HubSpot — TechCrunch AI · 2026-11-16
- Did AEO really diverge from SEO? QueryBurst audits Profound's 33 recommendations — gaganghotra_ · 2026-11-16
- IDC's 70-page report asks why 350+ national AI models outside US and China failed to compete — perilli · 2026-11-16